Allogene Therapeutics (ALLO)

Common Shares

Sell: $1.20|Buy: $1.23|Change: 0.05 (-3.97%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

This share can be held in a Dealing account Stocks and shares ISA Lifetime ISA JISA SIPP

Company profile

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Address

210 East Grand Avenue
South San Francisco
CA
USA
94080

Telephone

+1 650 457-2700

Website

https://www.allogene.com

Sector

Healthcare

Forecast key dates

Name	Key Date
Allogene Therapeutics Inc Second Quarter Earnings Conference Call for 2026	2026-08-13T17:00:00
Allogene Therapeutics Inc Second Quarter Earnings Results for 2026	2026-08-13T00:00:00
Allogene Therapeutics Inc Annual General Meeting for 2026	2026-06-18T08:00:00
Allogene Therapeutics Inc First Quarter Earnings Conference Call for 2026	2026-05-13T17:00:00
Allogene Therapeutics Inc First Quarter Earnings Results for 2026	2026-05-13T00:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025	2026-03-13T17:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Results for 2025	2026-03-13T00:00:00
Allogene Therapeutics Inc Annual Report for 2025	2026-03-13T00:00:00
Allogene Therapeutics Inc Third Quarter Earnings Conference Call for 2025	2025-11-07T17:00:00
Allogene Therapeutics Inc Third Quarter Earnings Results for 2025	2025-11-07T00:00:00

Previous key dates

Name	Key Date
Citi's 2025 Biopharma Back to School Summit	2025-09-03T10:30:00
Allogene Therapeutics Inc Second Quarter Earnings Conference Call for 2025	2025-08-13T17:00:00
Allogene Therapeutics Inc Second Quarter Earnings Results for 2025	2025-08-13T00:00:00
Allogene Therapeutics Inc Annual General Meeting for 2025	2025-06-18T08:00:00
Jefferies Global Healthcare Conference	2025-06-04T16:55:00
TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA	2025-05-27T12:30:00
Allogene Therapeutics Inc First Quarter Earnings Conference Call for 2025	2025-05-13T17:00:00
Allogene Therapeutics Inc First Quarter Earnings Result for 2025	2025-05-13T00:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Conference Call for 2024	2025-03-13T17:00:00
Allogene Therapeutics Inc Fourth Quarter Earnings Result for 2024	2025-03-13T00:00:00
Allogene Therapeutics Inc Annual Report for 2024	2025-03-13T00:00:00
TD Cowen 45th Annual Health Care Conference	2025-03-05T11:50:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference	2025-02-12T15:20:00
43rd Annual J.P. Morgan Healthcare Conference	2025-01-15T15:00:00
36th Annual Piper Sandler Healthcare Conference	2024-12-03T08:00:00
The Citizens JMP Hematology and Oncology Summit (Virtual)	2024-12-02T11:00:00
Jefferies London Healthcare Conference	2024-11-20T05:00:00
Stifel 2024 Healthcare Conference	2024-11-18T08:35:00
Allogene Therapeutics Inc Third Quarter Earnings Conference Call for 2024	2024-11-07T17:00:00
Allogene Therapeutics Inc Third Quarter Earnings Result for 2024	2024-11-07T00:00:00
Goldman Sachs Cell Therapy Day	2024-10-01T13:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.